I
schemia and subsequent reperfusion (IR) result in secondary remote organ dysfunction because of the leaking of toxic metabolites from the damaged organ into the circulation or their generation within it. 1 Remote reperfusion injury was attributed to circulating xanthine oxidase (XO) 1, 2 and to its byproducts, stress-generated reactive oxygen species (ROS), which can also play a deleterious role independently from XO. 3 Very few experimental antioxidants are clinically safe. Mannitol (MN), a known scavenger of the hydroxyl radical ͓ · OH Ϫ ͔, reduces oxidant-derived injury to the kidney, heart, and lung. [4] [5] [6] MN was earlier found to be partially effective in protecting the aorta from remote organ-induced injury 7 ; this was recently confirmed in a similar study on the lung. 8 A clinical study by Kretzchmar et al., however, found MN to be ineffective in attenuating lung reperfusion syndrome after abdominal aortic aneurysmectomy. 9 Although this finding could have been the result of inhibition of MN by various blood and tissue factors, 10 it raises some questions about MNЈs potential effectiveness in preventing IR-induced remote reperfusion syndromes.
N-acetylcysteine (NAC), another clinically used drug, 9,11 is a precursor of the physiologic antioxidant glutathione in its reduced form (GSH). GSH acts either directly or via the glutathione peroxidase catalysis that helps to scavenge the ROS generated in the extra-cellular medium. 12 Exogenous GSH cannot enter the intact cell 12 and needs external cysteine to transverse the cell membrane and replenish thiols: 13 NAC provides such compounds. Conflicting data, however, have recently appeared in the literature regarding the therapeutic efficacy of NAC in clinical settings. 9, 11, 12 It was demonstrated that NAC was effective in protecting the lung from reperfusion injury, but that it did so in a dose-limited and narrow-range fashion. 14 Because of possible species, organ, dose, or even interindividual variability of efficacy of either drug when administered separately, and because of the above-mentioned contentious data, the question arose as to whether combining both compounds would result in their potentiating one another and thereby augment their efficacy in preventing lung reperfusion injury. The current study aimed to answer this question.
MATERIALS AND METHODS

General Animal Surgery
This study was performed in accordance with the PHS policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the Care and Use of Laboratory Animals, and the Animal Welfare Act (7U.S.C. et seq.). The animal use protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of Tel Aviv Sourasky Medical Center. Adult male Wistar rats (n ϭ 216, 108 donating the livers and the other 108 donating the lungs) weighing 340 to 420 g were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg); they died from exsanguination while under anesthesia.
Isolated Perfused Liver and Lung Preparation
A laparotomy was performed and the liver was isolated and perfused with hemoglobin-free, oxygenated, modified Krebs-Henseleit solution (Krebs) via the portal vein and the suprahepatic inferior vena cava as previously described. 1 The liver was then placed in a water-insulated environmental chamber (constant temperature 37°C) and perfused at a rate of 4 mL/min/g liver ideal weight (42-48 mL/min) or as required to maintain a normal exiting pH in the perfusate during stabilization. 6 Lungs from different animals were tracheostomized and ventilated (95% air-5% CO 2 , 1 mL/100 g body weight tidal volume and 40 breaths/min) and perfused via the main pulmonary artery and left atrium with Krebs containing 5% (wt/vol) bovine serum albumin. The addition of albumin to the Krebs solution did not interfere with any of the biochemical analyses. 1, 6, 7, 14 End-expiratory pressure was maintained at ϩ2 cm H 2 O and pulmonary venous pressure was kept constant at ϩ2.5 cm H 2 O. The lungs were then suspended from a force displacement transducer (Grass Instruments Co., Quincy, Mass.) within an acrylic, water-insulated (37°C) environmental chamber. The lung perfusion rate ranged between 15 to 18 mL/min. 
Drug Protocol
The postliver reperfusate was reconstructed before entering the lungs in the appropriate groups (see below) to contain a high or a low dose of the experimental drugs (weight/rat body weight, mmol). MN (Baxter, Ashdod, Israel) was administered either alone or in combination with a high or low dose of NAC (BF Goodrich Diamalt GmbH, Raubling, Germany); the doses of NAC could also be administered singly (see below). The solutions were always isosmotic. A pilot study in our laboratory had found that doses less than 0.44 mmol MN and 0.25 mmol NAC were totally ineffective. Figure 1 illustrates the experimental protocol. Following 30 minutes of stabilization (Fig. 1A) , an isolated liver was perfused for 2 hours or made globally ischemic (flow arrest). Toward the end of this period, one lung was isolated and stabilized for 30 minutes (Fig. 1B) . At this point, each liver was connected in-series to a lung, so that the hepatic effluent was directed into the pulmonary circulation through a heated membrane oxygenator (Fig. 1A,B) . The pair of organs was perfused together for 15 minutes after which the liver was removed from the circuit and the lung was left to recirculate for additional 45 minutes with the effluent that had been accumulated during the earlier 15-minute serial reperfusion period (B). While the liver was always perfused in a single-pass mode, the lung was perfused mainly in a closed-loop recirculation mode.
Experimental Protocol
There were nine experimental study groups with a total of 12 replicates each. Half (n ϭ 6) of the livers in each group underwent 2 hours of perfusion (control subgroups) and the other half underwent ischemia (IR subgroups), thus yielding 18 subgroups. Each liver had a normal lung attached to it during reperfusion. The nine study groups underwent the following protocol: lungs not treated (i.e. Krebs not containing any drug) in one group whereas the lungs in the other eight groups were treated starting at the reperfusion phase (of either control or IR livers) with one of the drug protocols via a side arm attached to the postliver prelung circuit. These eight protocols consisted of four monotherapies (two MN doses [one low and one high dose] and two NAC doses [one low and one high dose]) and four bitherapies (combinations of the four monotherapies) ( Table 1) .
Data Collection
Samples for laboratory tests were taken every 15 minutes, while physiologic variables were recorded continuously (see below). Additional laboratory sampling time points were at 1, 5, and 10 minutes during the in-series reperfusion period.
Biochemical Analyses
Following previous demonstrations that increased circulating hepatocellular compounds and enzymes was indicative of liver damage induced by a 2-hour IR that was later associated with secondary organ damage, 1, 6, 7, 14 the activity of aspartate aminotransferase (AST) in the bronchoalveolar lavage (BAL) was assessed in duplicate to mark liver damage, using a commercial kit of Roche-Boehringer (Mannheim GmbH Diagnostic, Mannheim, Germany) and a Hitachi 747 (Tokyo, Japan) analyzer. The determination of the total XO ϩ XDH (the oxidized and reduced forms) activity was aimed at indirectly quantifying the potential detrimental activity of ROS. Total XO was analyzed in the BAL fluid following the method of Hashimoto 15 and as previously described. 7, 14 Portions of lung tissue were also used to determine XO. Glutathione in its reduced form (GSH) was measured in the tissue, using a specific assay kit (Calbiochem 354102 San Diego, Calif.).
Lung Physical Data
These parameters comprised pulmonary perfusion pressure, intra-experimental lung weight gain, peak ventilatory pressure, and BAL volume and content. Pressures were measured directly via pressure transducers and continuously recorded on a physiologic recorder (Grass Model 7D polygraph, Grass Instruments Co., Quincy, Mass.). At the end of the experiment, the lung's airways were gently flushed three times with 1 mL of warm saline through the trachea, and the fluid was left to drain out passively. A portion from each lung was then weighed and dried at 80°C for 7 days so that the wet-weight-to-dry-weight ratio (WDR) could be calculated. This index was found to linearly represent alveolocapillary membrane dysfunction 1 and was used in the current investigation since the model mimicked clinical lung injury associated with fluid movement into the lung tissue.
Statistics
The data variables were summarized as means Ϯ SEM. At each time point, a post hoc analysis was done using a two-way analysis of co-variance (ANCOVA) with repeated measures to compare changes within lung groups over time The comparisons between group means were carried out by the Student NewmanKeuls test; enzymes concentrations in the BAL or in the lung tissue were analyzed by the same test. The level of significance was set at p Յ 0.05.
RESULTS
Most of the values for the parameters in the controltreated subgroup of lungs were almost identical to those in the nontreated subgroup. The data of all these lungs, therefore, are reported cumulatively and are collectively referred to as "controls," unless otherwise specified. Every group (n ϭ 12/group) was divided into two subgroups (n ϭ 6/each), one consisting of lungs paired to control and one to IR livers. Each lung preparation was separately stabilized for 30 min before being paired to a liver and perfused with its effluent.
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Biochemistry of the Double-Organ Model
Both the fractionated BAL indices (i.e. fluid volume retrieved after each flush and its contents, data not shown) and the total BAL volumes retrieved from the control lung subgroups were significantly ( p Ͻ 0.05) lower compared with those obtained in the IR-0 and the two low-dose (IR-M44, IR-N25) monotherapy subgroups. The higher two monotherapies (IR-M55, IR-N37) and all four bitherapy subgroups of lungs (IR-M44N25, IR-M55N25, IR-M44N37, and IR-M55N37) yielded a similar total volume as that of the controls (Table 2) . A similar trend was observed for the volume-calculated solutes, i.e. AST and the total XO activities. Figure 2 (upper plane) shows the total XO activity in the lung tissue that was similarly low in the various control subgroups. It increased ( p Ͻ 0.01) to levels above those of the controls in the IR-0 and, to a significantly lesser degree, in the four monotherapy-treated lungs. Among these latter four, the higher dose monotherapies were associated with less XO activity than the lower dose ones. The activity in the fourbitherapy subgroups was low when compared with the IR-0 lungs and, more importantly, in comparison to all monotherapy-treated subgroups, with the activity becoming significantly ( p Ͻ 0.05) lower in three of the corresponding bitherapy-control counterparts.
Tissue GSH content in the various subgroups is also displayed in Fig. 2 (lower plane) . The content in all the control monotherapy-treated lungs remained almost unchanged from that of the nontreated controls, except for the N37 lungs in which the GSH value was 72% higher than that of the control lungs. The bitherapy-treated control lungs contained up to 218% more GSH than the nontreated ones, equivalent to there being 116% more GSH than the sum of GSH assessed in the pair of monotherapies that composed each of these bitherapies. In the various IR-paired-treated lungs, the GSH values were all lower by 26 to 38% of their control counterparts. The maximum GSH value in any monotherapy IR lungs was 51% higher than the IR-0 content. The content in any of the four IR-bitherapy-treated lungs was higher by 64 to 124% than the sums of their corresponding two monotherapies' values and by 46 to 279% more than the IR-0 value. The lowest figure of GSH in either control or IR biotherapy-treated subgroups pertained to the M44N25 lungs, i.e. those treated with the combined two low-dose monotherapies.
Pulmonary Vascular and Ventilatory Data
Pulmonary perfusion pressure values began to increase among the IR-paired lungs starting at the first minute of reperfusion (Fig. 3) . The two low-dose IR monotherapies (M44, N25) only slightly reduced the significant ( p Ͻ 0.01 vs. controls) pressure increase detected in the IR nontreated (IR-0) lungs. The two high-dose monotherapies (M55, N37) and all four bitherapies were effective in protecting the lungs from injury compared with the controls' values.
Peak ventilatory pressure (Fig. 4) remained unchanged in all the control and the four bitherapy-treated lungs. The two IR high-dose monotherapy-treated lungs had the pressure in-between the controls' and the bitherapy-treated lungs' on the lower level and the IR-0, the IR-M44-or the IR-N25-treated lungs on the higher values. The response patterns of the latter two regimens demonstrated a plateau effect.
Lung Weight Gain
There were no significant intra-experimental weight gains in either the control groups, in the four bi-therapy subgroups of lungs or the two IR high-dose monotherapy (M55, N37)-regimen lungs (Fig. 5) . In contrast, the two low-dose monotherapy (M44, N25)-treated lungs gained as much weight as did the IR-0 subgroup.
WDR
The IR livers' averaged WDR was 5.3 Ϯ 0.2 compared with the averaged WDR of 4 Ϯ 0.3 ( p Ͻ 0.05) for the control subgroups of livers, indicating IR-induced liver damage. The IR-M44 and IR-M25 lungs were the only subgroups whose WDRs were similar to that of the IR-0 lung subgroup ( Table 2 ). The rest of the IR-paired and treated lungs, including the ones in the two high-dose monotherapy groups, had WDRs that were similar to those of the controls and they were significantly ( p Ͻ 0.01) lower than the values of the two IR low-dose monotherapy and the IR-0 subgroups (Table 2) .
DISCUSSION
The hypothesis of there being an additive or even a synergistic protective effect of MN, a ROS scavenger, and NAC, a GSH precursor as well as a ROS scavenger, on reperfusion lung The Journal of TRAUMA Injury, Infection, and Critical Care damage after liver IR was confirmed in the present study. The postulated ROS-induced alveolocapillary disruption that generates movement of fluid and large molecular weight compounds (e.g. AST) from the vascular compartment into the lung interstitium provided the pathophysiologic basis for the present lung reperfusion injury.
1 Subsequent demonstration of the dose-specific effectiveness of NAC and of MN in preventing such damage provided the direction for this drug therapy investigation. 7, 8, 14 The first important result of this study was the demonstration that the combination of the two lower dose regimens (N25, M44), ineffective when administered individually, prevented ventilatory-and perfusion-related injuries in the IR liver-paired lungs, thus providing evidence of a clear advantage of the combination approach over a single dose monotherapy. This therapeutic effect recurred when any of MN and NAC doses were combined. These drug combinations also yielded an additive XO-reducing activity and augmented the capacity of each of the single doses in replenishing GSH in the IR-paired lungs' tissues. This latter effect was observed in the controls and in the IRs to a similar degree.
Various double-organ models have been used to assess the direct detrimental effects of hepatic IR in damaging remote organ functions 1, 6 and NAC provided a dose-specific protection of the latter.
14 The working hypothesis in those studies was that the damaged liver induces remote functional impairment via an oxidative process, which is initiated and maintained in an active state by the high levels of circulating XO, possibly by its generated ROS byproducts. 1,16 -18 Because the effectiveness of NAC in preventing secondary injuries was dose-limited, 14 as was that of MN, 7 it was now reasoned that their protective effects on the lung could be augmented if both scavengers were administered in combination.
The various drug combinations comprised two effective monotherapy doses (MN 0.55 mmol and NAC 0.37 mmol) and two ineffective ones (MN 0.44 mmol and NAC 0.25 mmol). The effect of one that could be exerted on the other was investigated by crossmatching them. Thus, the two low doses satisfactorily protected the lungs when given simultaneously because they potentiated each other. Similarly, the combination of M55 with N25 (the M55N25 regimen) which contained the MN dose that had a proven efficacy in isolation and the NAC dose that was ineffective when used alone, was actually more efficient than each of the two regimens alone because of an augmentation effect. Also, when each of the two MN doses was concomitantly administered with NAC 0.37 mmol, the anticipated lung protection (especially in light of the proved M55 and N37 effectiveness) became most apparent by the blockade of XO activity and especially the lung tissue GSH content that increased Ͼtwofold compared with the sum of the corresponding monotherapies. There was also only minimal rise in the volumes and the levels of AST that were retrieved in the BAL (as in the IR-N37, IR-M55, or in the IR-M55N25 lungs), which expresses these therapies' capacity to prevent the overt changes in alveolocapillary permeability (that lead to movements of abnormal amounts of fluids and solutes into the alveoli, as occurs clinically upon the development of acute lung injury). These therapeutic effects coincided with the presently recorded better ventilatory and perfusion parameters and lack of weight gain.
There appear to be no data in the literature to indicate a positive reciprocal effect of the two drugs in reducing primary or secondary lung injury. The reason could be because of their being of dissimilar antioxidant activity. MN is an ͓ · OH Ϫ ͔ scavenger and quenches this and other ROS, thus reducing their injurious activity both extra-and intracellularly. 4, 5 NAC has long been the cornerstone compound used for the investigation of the thiol precursors. 19 It has been the most frequently investigated glutathione prodrug for the prevention of post-transplant IR effects in the liver 12 and, because this model could mimic such circumstances, NAC seemed to be the right choice. It was also demonstrated that NAC participates in scavenging XO-and its generated ROS within the circulation and in the lung tissue, besides its enhancing GSH replenishment in the organ.
14 This study, however, has several limitations in that it neither directly measured ͓ · OH Ϫ ͔ or other specific ROS nor did it investigate the molecular mechanism by which the drugs' reciprocal pharmacological lung protection was obtained. ROS were not measured because the direct and precise measurement of free radicals, especially hydroxyls, is difficult to obtain in vivo because of their extremely short half-lives. It has been documented, however, that XO activity faithfully represents ROS' toxic effects, PMNL recruitment and organ function. 1, 6, 16 Which drug potentiated the other and was the effect merely additive or a synergistic reciprocal one? Did NAC augment MNЈs quenching ROS, perhaps via its known oxidant scavenging potentials or, by quenching ROS, did MN enable more NAC to be available for GSH replenishment? The present data failed to provide a conclusive answer to these questions, and more studies will be needed before the issues are put to rest. The bitherapy-additive reduction of XO activity in the BAL and within the tissue could, indeed, be explained by either alternative, because each drug could achieve the same objective, i.e. the re-establishment of the antioxidant dominance. 6, 14, 19, 20 The fact that XO activity was reduced to even below the control lung activity is not a new finding. 1 The second marker for antioxidant activity, i.e. the GSH level in the lungs' tissues, both in the control-and in the IR-added bitherapies, could be explained by MNЈs quenching the activity of the XO (and the generated ROS), thus leaving more NAC available to generate more GSH. Indeed, when M44 or M55 were added to either the N25 or N37 regimen, the production of GSH was superior to either NAC singledose capacity. At the same time, however, potentiation of MNЈs quenching effect by NAC would also have led to a similar dose-dependent preservation of GSH because this enzyme would have been consumed to a lesser degree in the presence of a lower circulating stress oxidative activity.
14 A dose-response protocol aimed at studying either eventualities, as well as the possible synergistic enhancement of the two drugs (as suggested by the plateau effects of the single doses) is currently under investigation.
The clinical importance of remote organ injury and the possible means for its prevention after organ transplantation lie in the fact that to date none of the organ preservation solutions used by the different transplantation groups has proved to produce consistently optimal results. Thus, livers subjected to prolonged ischemia (during transportation, storage, or grafting) could later induce acute lung reperfusion injury, 21 similar to that shown in the current report. Nevertheless, lung dysfunction can also follow limb ischemia 22 or the release of a tourniquet 23 placed during trauma or severe hemorrhage, and aortic aneurysm repair. 9, 20, 24 In conclusion, the combination of NAC and MN, even at low doses that are not effective when each is given alone, afforded a higher grade of protection against oxidativeinduced lung reperfusion injury, when administered as reperfusion process starts. Further studies, however, are still warranted to assess this interaction in other organ and reperfusion models.
